Tadalafil and Pulmonary Arterial Hypertension

Clinical Therapeutics

Volumn 34, Issue 1, 2012, Pages 257-

  Frumkin, Lyn ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TADALAFIL;

DRUG HALF LIFE; HUMAN; LETTER; PULMONARY HYPERTENSION; THERAPY EFFECT;

CARBOLINES; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 84856154933     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.034     Document Type: Letter

References (3)

1. Arif S.A., Poon H. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. Clin Ther 2011, 33:993-1004.
2. Adcirca 2009, [package insert], Eli Lilly & Co, Indianapolis, Ind, 2011.
3. Galiè N., Brundage B.H., Ghofrani H.A., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.